New Research Maps Emerging Therapies for Antiphospholipid Syndrome

Antiphospholipid syndrome, or APS, is an autoimmune condition that causes the immune system to produce misguided antibodies that make the blood prone to clotting and, in pregnancy, can lead to serious complications like miscarriage or preeclampsia. At the center of this process are antiphospholipid antibodies, particularly those targeting a protein called beta-2 glycoprotein I. When these antibodies attach to that protein, they activate a cascade of inflammatory and clotting responses across multiple cell types, including platelets, blood vessel lining cells, and immune cells.

A major 2025 review published in Frontiers in Immunology synthesizes decades of research and recent advances to provide an updated picture of how APS causes disease and how clinicians are now approaching treatment. The authors, a team from Dalian Medical University in China, highlight how our understanding of APS has evolved from a purely clotting-focused condition to a complex, antibody-driven autoimmune disease that warrants immunological interventions alongside traditional anticoagulation.

Anticoagulants like warfarin have been the backbone of APS treatment for years, reducing the risk of clots in people with confirmed antibodies and prior events. But anticoagulation does not address the root cause, and researchers have long sought therapies that target the immune system directly. The new review summarizes a growing number of clinical trials exploring therapies that deplete or suppress B cells and plasma cells, which are the immune cells responsible for producing the harmful antibodies. Agents under investigation include rituximab, belimumab, telitacicept, zanubrutinib, and anti-CD38 monoclonal antibodies. Most striking are early-phase trials exploring CAR-T and CAR-NK cell therapies that target the CD19 protein on B cells, borrowing approaches originally pioneered in blood cancers.

The DARE-APS trial represents one of the most cutting-edge efforts, testing daratumumab, a plasma cell-targeting antibody already approved for multiple myeloma, in patients with primary APS. The goal is to see whether depleting antibody-producing plasma cells can reduce or eliminate the pathogenic antiphospholipid antibodies themselves. If successful, this approach could shift APS management from lifelong anticoagulation to antibody elimination.

Diagnostic tools are also improving. The adjusted Global Antiphospholipid Syndrome Score, known as aGAPSS, helps clinicians quantify a patient's individual risk for thrombosis based on their specific antibody profile and clinical features. Metabolomic profiling and non-traditional biomarkers such as anti-phosphatidylserine/prothrombin antibodies are being studied as additional tools to better identify high-risk patients and guide therapy decisions.

For patients and caregivers living with APS, these developments represent a meaningful shift in how the disease may be managed in the coming years. While anticoagulation remains the standard of care today, the expanding pipeline of immune-targeted therapies offers genuine hope for approaches that address the underlying biology of the condition rather than simply managing its consequences. Researchers caution that many of these strategies are still in early trials, and larger studies are needed to determine long-term safety and efficacy.